NEW YORK (GenomeWeb) – Myriad Genetics this week denied allegations of patent infringement levied against it in a US District Court by LabCorp subsidiary Esoterix Genetic Laboratories (EGL), arguing that its myRisk Hereditary Cancer panel and related services do not make use of the digital PCR technology covered in the intellectual property at the center of the dispute.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.